Leadership capability to benefit company’s AI activities

AI provider BenevolentAI has announced the appointment of Dr. Joerg Moeller, PhD, MD, as Chief Executive Officer and Executive Board member. A strong advocate of AI adoption, he has initiated several drug discovery collaborations and also forged strategic business development transactions through out-licensing assets as well as partnerships.

Most recently, Dr. Moeller served as EVP, Head of Global Research and Development and Member of the Global Leadership Team of LEO Pharma, where he re-organised and re-structured the organisation to support its growth and innovation ambitions.

He was also at Bayer AG for over 20 years, rising to EVP, Head of Pharmaceuticals Research and Development and Member of the Executive Committee of the Pharmaceuticals Division of Bayer. He successfully managed development and global product approvals, redefined Bayer’s pipeline strategy and brought on external strategic AI collaborations.  Dr. Moeller, who currently serves on the Board of US biotech Secura Bio, graduated as a Doctor of Medicine and holds a PhD from Ruhr University Bochum, Germany.

Dr. Moeller will be based in the London headquarters of BenevolentAI and Dr. François Nader will now revert to his previous position of Independent Non-Executive Chair.

Welcoming Dr Moeller, Dr. Nader said: “Along with the rest of the Board, I am delighted to welcome Joerg. He is an outstanding leader with extensive experience across all stages of R&D. With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform™ to deliver our patient-centric revenue generating strategy.”

Dr. Moeller, added: “I am excited by the opportunity to lead BenevolentAI. I believe the Company is well-positioned to further capitalise on its Platform, pipeline and research capabilities in order to strengthen the Company’s market position and continue to build its commercial activities. I am passionate about fostering a culture of excellence, innovation, and diversity and I look forward to working with the Board, the Leadership Team and BenevolentAI employees to create value for all its stakeholders ultimately helping to deliver treatments to the patients who need them.”

More information online